Loading
Group patients by why their last drug stopped working, then test the combination designed to fix that specific failure, whatever the cancer.
Progression biopsies and ctDNA now reveal resistance mechanisms (SLFN11 loss for topoisomerase-1 payloads, MET amplification for EGFR inhibitors, RB loss for CDK4/6 inhibitors). A basket trial enrolling by mechanism would test the matched rescue combination (for example ATR inhibitor plus the same ADC for SLFN11-low tumours) across histologies, converting a resistance hypothesis into a trial in months.
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Payload-class switching as the rule for ADC sequencing, Too many combinations to test, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Acquired resistance to every therapy.
Shares Payload-class switching as the rule for ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Too many combinations to test, CDK4/6 inhibitors, Acquired resistance to every therapy.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.